What is InduPro?
InduPro is a pioneering biotechnology firm specializing in proximity-based therapeutics. The company focuses on the precise manipulation of protein interactions on cell surfaces to develop innovative treatments for complex diseases. By defining the role of spatial relationships in biological systems, InduPro is creating a new class of drug therapies that address unmet medical needs. The company maintains a collaborative research model, working alongside industry giants like Lilly to validate and scale its proprietary platforms. Its multidisciplinary team, comprised of experts from academia, pharma, and biotech, is dedicated to translating complex scientific insights into life-saving clinical solutions.
How much funding has InduPro raised?
InduPro has raised a total of $162M across 2 funding rounds:
Series A
$85M
Series B
$77M
Series A (2024): $85M with participation from Vida Ventures, Emerson Collective, and The Column Group
Series B (2026): $77M led by The Column Group, Sanofi, Lilly, MSD, Solasta Ventures, Vida Ventures, and Emerson Collective
Key Investors in InduPro
Vida Ventures
Vida Ventures is a next-generation life sciences investment firm founded by scientists and entrepreneurs, focused on funding breakthroughs in biomedicine with approximately $1.7 billion under management.
Emerson Collective
Emerson Collective invests in purpose-driven entrepreneurs and innovators, focusing on complex challenges in areas such as human flourishing and scientific advancement.
The Column Group
The Column Group is a venture ecosystem dedicated to advancing scientific innovation in the life sciences, utilizing an edge-to-edge investment model to nurture technology platforms from inception to exit.
What's next for InduPro?
With the recent infusion of capital, InduPro is poised to transition from early-stage platform validation to more advanced clinical development. The strategic focus will likely center on expanding its therapeutic portfolio and deepening its collaborative partnerships with global biopharmaceutical leaders. As the company scales, it will prioritize the optimization of its proximity-based technology to address a broader range of indications, including oncology and immunology. The continued backing from specialized life sciences investors provides the necessary runway to navigate the rigorous regulatory and clinical milestones required to bring next-generation medicines to market, ultimately aiming to redefine the standard of care for patients worldwide.
See full InduPro company page
